Form 4: CervoMed Director Frank Zavrl Receives Equity Grant

Director Frank Zavrl was granted an option to purchase 8,150 shares of CervoMed common stock following his election to the board.

Summary

• Director Frank Zavrl received a stock option grant for 8,150 shares of CervoMed Inc. (CRVO) common stock.
• The grant was issued on June 8, 2026, in connection with his election to the board of directors at the 2026 Annual Meeting.
• The options have an exercise price of $2.91 per share.
• The options vest in 1/12th increments monthly over one year, starting June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized compensation practice for non-employee directors.

Negatives

• Minor dilution of existing shareholders due to the issuance of new stock options.

Risks

• Continued service requirement for vesting of the equity award.

Future Outlook

The options vest monthly over a one-year period, contingent upon the director's continued service to the company.

Management Comments

• The grant is in accordance with the terms of the Issuer's non-employee director compensation policy.

Industry Context

StockSavvy.ai notes that equity grants for board members are standard corporate governance practice to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical non-employee director compensation packages for small-cap biotechnology firms.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders due to the small size of the equity grant.

Next Steps

• Vesting of options beginning June 30, 2026.

Key Dates

Keywords

CervoMed, CRVO, Form 4, Director Compensation, Equity Incentive Plan, Insider Transaction